Objectives To evaluate changes in demographic, clinical and histological presentation, and
prognosis of lupus nephritis (LN) over time. Patients and methods We studied a multicentre …

Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre
Registry Page 1 Clinical and Experimental Rheumatology 2015; 33: 449-456. Efficacy and …

Objective. We report the first comparison between rituximab (RTX) and either MMF or CYC
pulses in the treatment of active LN. Methods. Fifty-four patients with active LN received …

Lupus nephritis (LN) treatment requires an initial intensive period of therapy followed by a
long-term maintenance treatment in order to stabilize disease control and eventually reach …

Few studies have correlated serum biomarkers with renal histology, the gold standard for
renal activity, in lupus nephritis (LN). We tested a panel of autoantibodies and complement …

Background The optimal dosing and the efficacy of rituximab for primary membranous
nephropathy (PMN) has not been established. This multicentric prospective study evaluates …

There is agreement that early diagnosis and aggressive treatment of lupus nephritis
exacerbations are of paramount importance to achieve remission and prevent the …

Background A renewed interest for activity and chronicity indices as predictors of lupus
nephritis (LN) outcome has emerged. Revised National Institutes of Health activity and …

No data are available about the impact of pregnancy on the long-term outcome of lupus
nephritis. Thirty-two women with lupus nephritis with a 10-year follow-up after their first …

Rationale & Objective Idiopathic retroperitoneal fibrosis (IRF) is a rare disorder of unknown
cause. Medical therapy can induce remission, but disease relapses are common. This study …